Get the Stockscreener App
6.14
0.66%
0.04
Immatics N V stock is traded at $6.14, with a volume of 1.36M.
It is up +0.66% in the last 24 hours and up +29.54% over the past month.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
See More
Previous Close:
$6.10
Open:
$6.06
24h Volume:
1.36M
Relative Volume:
1.86
Market Cap:
$722.01M
Revenue:
$58.49M
Net Income/Loss:
$-105.04M
P/E Ratio:
-4.7242
EPS:
-1.2997
Net Cash Flow:
$-13.78M
1W Performance:
+3.37%
1M Performance:
+29.54%
6M Performance:
-14.48%
1Y Performance:
-52.81%
1-Day Range:
$6.05
$6.38
1-Week Range:
$5.895
$6.38
52-Week Range:
$3.30
$13.12
Immatics N V Stock (IMTX) Company Profile
Compare IMTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
6.14 | 722.01M | 58.49M | -105.04M | -13.78M | -1.2997 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Initiated | Deutsche Bank | Buy |
| Oct-07-24 | Initiated | Piper Sandler | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Nov-20-20 | Initiated | BofA Securities | Buy |
| Sep-22-20 | Initiated | Goldman | Buy |
| Jul-27-20 | Initiated | SVB Leerink | Outperform |
| Jul-24-20 | Initiated | Jefferies | Buy |
View All
Immatics N V Stock (IMTX) Latest News
These Numbers Reveal How Powerful Immatics N.V (NASDAQ: IMTX) Stock Is - Stocksregister
Learn to Evaluate (IMTX) using the Charts - news.stocktradersdaily.com
Cantor Fitzgerald Comments on Immatics FY2026 Earnings - Defense World
Two Sigma Investments LP Sells 36,345 Shares of Immatics (NASDAQ:IMTX) - Defense World
Immatics (NASDAQ:IMTX) Shares Sold by Two Sigma Advisers LP - Defense World
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME - Revista ADVFN
Immatics rises on data from early stage cell therapy trial - MSN
Millennium Management LLC Has $1.11 Million Holdings in Immatics (NASDAQ:IMTX) - Defense World
Immatics: Taking Off On A PRAME Rocketship - Seeking Alpha
Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect? - Yahoo Finance
Immatics Announces Annual General Meeting for June 2025 - TipRanks
immatics n.v. announces upcoming annual general meeting By Investing.com - Investing.com South Africa
immatics n.v. announces upcoming annual general meeting - Investing.com
Immatics (IMTX) Soars After Positive Trial Results for Cell Ther - GuruFocus
Cantor Fitzgerald reiterates overweight rating on Immatics stock By Investing.com - Investing.com UK
Immatics Presents Promising IMA203 Data at ASCO 2025 - TipRanks
Form 6-K Immatics N.V. For: Jun 02 - StreetInsider
Northern Trust Corp Purchases 11,304 Shares of Immatics (NASDAQ:IMTX) - Defense World
Immatics (IMTX) Shares Promising Data from IMA203 Melanoma Trials | IMTX Stock News - GuruFocus
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 - GlobeNewswire
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO - GuruFocus
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma | IMTX Stock News - GuruFocus
Immatics N.V. Reports Promising Long-Term Efficacy and Safety Data from Phase 1b Trial of IMA203 PRAME Cell Therapy in Metastatic Melanoma - Nasdaq
PRAME Cell Therapy Shows 56% Response Rate in Melanoma Patients at ASCO 2025 | IMTX Stock News - Stock Titan
Immatics (NASDAQ:IMTX) Receives $17.00 Average Price Target from Analysts - Defense World
Immatics N.V. (IMTX) Stock Analysis: Uncovering a 163% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Long Term Trading Analysis for (IMTX) - news.stocktradersdaily.com
Immatics (NASDAQ:IMTX) Coverage Initiated by Analysts at Deutsche Bank Aktiengesellschaft - Defense World
D. E. Shaw & Co. Inc. Has $176,000 Stake in Immatics (NASDAQ:IMTX) - Defense World
Deutsche Bank Initiates Coverage of Immatics N.V. (IMTX) with Buy Recommendation - Nasdaq
Immatics (IMTX) Receives "Buy" Rating from Deutsche Bank | IMTX Stock News - GuruFocus
Deutsche Bank Initiates Coverage on Immatics With Buy Rating, $10 Price Target - marketscreener.com
Deutsche Bank Gives Immatics (IMTX) a Boost with Buy Rating and $10 Target | IMTX Stock News - GuruFocus
Deutsche Bank sets $10 target for Immatics stock on Buy rating - Investing.com UK
Immatics FY2025 EPS Forecast Increased by Cantor Fitzgerald - Defense World
Lacklustre Performance Is Driving Immatics N.V.'s (NASDAQ:IMTX) Low P/S - simplywall.st
The Manufacturers Life Insurance Company Sells 71,487 Shares of Immatics (NASDAQ:IMTX) - Defense World
We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely - Yahoo Finance
Immatics: Q1 Earnings Snapshot - CT Insider
Immatics Announces First Quarter 2025 Financial Results and Business Update - GlobeNewswire
Immatics NV earnings missed by €0.07, revenue topped estimates - Investing.com South Africa
Immatics NV reports results for the quarter ended March 31Earnings Summary - TradingView
IMTX Sees Revenue Decline, Highlights Advances in Melanoma Thera - GuruFocus
Immatics Reports Increased Q1 2025 Loss Amid Rising R&D Costs - TipRanks
Immatics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Immatics N V Stock (IMTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):